TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17584910
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy regimen consisting of vincristine (2 mg/m2), doxorubicin (90 mg/m2), cyclophosphamide (2,200 mg/m2) and ifosfamide (2,800 mg/m2/day x 5 days), etoposide (100 mg/m2/day x 5 days) over 51 weeks
Study: 9580247
Drug: Insulin Lispro
Normalized name: Insulin Lispro
DrugBank: Insulin lispro (DB00046)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Insulin Lispro (IL)
Study: 8155220
Drug: Daily 10-minute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily 10-minute perineal massage
Study: 2837078
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g elemental phosphorus as neutral sodium‐potassium phosphate in grape juice or in water
Study: 2837078
Drug: 1.7 g
Normalized name: Vaporizer 1.7 gallon
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.7 g NaCl in juice
Study: 2837078
Drug: 1.5 g
Normalized name: Vaporizer Vicks 1.5 gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 g phosphorus in juice
Study: 2837078
Drug: 1-1.5 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1-1.5 g phosphorus
Study: 29722944
Drug: Oral tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tadalafil once daily
Study: 29722944
Drug: Oral tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tadalafil on demand
Study: 29722944
Drug: Oral tadalafil
Normalized name: Tadalafil
DrugBank: Tadalafil (DB00820)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tadalafil once-daily + on-demand
Study: 23391033
Drug: Inlay preparations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Study: 23391033
Drug: Onlay preparations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay preparations, lithium‐disilicate glass‐ceramic (IPS e.max Press)
Study: 23391033
Drug: Inlay preparations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inlay preparations, zirconia ceramic (ICE Zirkon)
Study: 23391033
Drug: Onlay preparations,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onlay preparations, zirconia ceramic (ICE Zirkon)
Study: 18728526
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g fructose
Study: 18728526
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g fructose
Study: 18728526
Drug: 45 g
Normalized name: SODIUM CHLORIDE 0.045 g in 5 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 45 g fructose
Study: 16608040
Drug: Colchicine 1
Normalized name: colchicine 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Colchicine 1 mg per day (group A)
Study: 16608040
Drug: No antifibrotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antifibrotic agent (group B)
Study: 1426099
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C (HDAra-C) as a single agent for induction therapy
Study: 1426099
Drug: High-dose Ara-C
Normalized name: cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: High-dose Ara-C (HDAra-C) plus mAMSA
Study: 30452713
Drug: Albendazole treatment
Normalized name: Albendazole
DrugBank: Albendazole (DB00518)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Albendazole treatment (3-monthly for 1 year)
Study: 29215519
Drug: Transcervical Foley
Normalized name: CATHETER,FOLEY
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transcervical Foley catheter plus oxytocin infusion
Study: 25238439
Drug: Local infiltration
Normalized name: Autologous tumor infiltrating lymphocytes
DrugBank: Lifileucel (DB17107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local infiltration analgesia (LIA) with levobupivacaine (150 mg), ketorolac (30 mg), and adrenaline (0.5 mg)
Study: 15836710
Drug: Norfloxacin 400
Normalized name: norfloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norfloxacin 400 mg once daily with cisapride 20 mg twice a day
Study: 10480285
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human erythropoietin (rHuEpo) at a dose of 300 u/kg of body weight three times a week for 6 weeks
Study: 1919425
Drug: Adenosine infusion
Normalized name: Adenosine
DrugBank: Adenosine phosphate (DB00131)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adenosine infusion (108 +/- 6 micrograms kg-1 min-1)
Study: 29499745
Drug: Electroacupuncture (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture (EA) treatment, traditional EA treatment with de-qi sensation, 3 times per week for 12 sessions over 4 weeks.
Study: 29499745
Drug: Sham electroacupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham electroacupuncture treatment, without needle penetration and electrostimulation, 3 times per week for 12 sessions over 4 weeks.
Study: 17646219
Drug: Prednisone, 2
Normalized name: PredniSONE, 20 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone, 2 mg/kg/d up to 60 mg, on days 1 to 5
Study: 2506702
Drug: Neogluconin (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neogluconin (2.5 mg)
Study: 2506702
Drug: Euglucon (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Euglucon (5 mg)
Study: 27919627
Drug: Pemetrexed followed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed followed by erlotinib (150 mg orally once daily on days 2-17)
Study: 27919627
Drug: Pemetrexed alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed alone (500 mg/m2 intravenously on day 1)
Study: 26033398
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment without abciximab
Study: 26033398
Drug: Clopidogrel treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel treatment with abciximab
Study: 19692796
Drug: Ascorbate treatment
Normalized name: ascorbate
DrugBank: Ascorbic acid (DB00126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ascorbate treatment (intravenous vitamin C)
Study: 19692796
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (normal saline infusion)
Study: 16476851
Drug: Control (unchanged
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (unchanged therapy)
Study: 15379272
Drug: rhTPO 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhTPO 1.0 microg/(kg x d) administered subcutaneously for up to 14 days after chemotherapy
Study: 14964737
Drug: Intramuscular bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular bupivacaine
Study: 8992351
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment to lower LDL cholesterol levels (with lovastatin and, if needed, cholestyramine)
Study: 8992351
Drug: Moderate treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate treatment to lower LDL cholesterol levels
Study: 8992351
Drug: Aggressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive treatment to lower LDL cholesterol levels
Study: 8256082
Drug: Glypressin (intravenous)
Normalized name: Lypressin
DrugBank: Lypressin (DB14642)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Glypressin (intravenous)
Study: 3547298
Drug: Buffy coat
Normalized name: Leucocyte buffy coat
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffy coat transfusions (15 mL/kg)
Study: 23163616
Drug: Larazotide acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larazotide acetate 1 mg
Study: 23163616
Drug: Larazotide acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larazotide acetate 4 mg
Study: 23163616
Drug: Larazotide acetate
Normalized name: Larazotide
DrugBank: Larazotide (DB05645)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Larazotide acetate 8 mg
Study: 11390253
Drug: alpha‐methyl‐para‐tyrosine (AMPT)
Approvals — FDA: no, EMA: no, PMDA: no
Description: alpha‐methyl‐para‐tyrosine (AMPT) 1-g doses
Study: 11390253
Drug: promethazine (active
Approvals — FDA: no, EMA: no, PMDA: no
Description: promethazine (active placebo) 50-mg doses
Study: 9415535
Drug: High-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose intravenous methylprednisolone (1000 mg per day) for five days
Study: 8301876
Drug: TJ-960 (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: TJ-960 (7.5 g per day for 8 weeks)
Study: 3771949
Drug: Uniphyl, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl, 800 mg four times a day (qd)
Study: 3771949
Drug: metered-dose albuterol,
Approvals — FDA: no, EMA: no, PMDA: no
Description: metered-dose albuterol, active, 180 micrograms four times a day (qid)
Study: 3771949
Drug: Uniphyl, 400
Normalized name: Uniphyl, 400 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl, 400 mg twice daily
Study: 3771949
Drug: Uniphyl, 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl, 800 mg qd; placebo, two puffs qid
Study: 3771949
Drug: Uniphyl, 400
Normalized name: Uniphyl, 400 mg/24 hours oral tablet, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Uniphyl, 400 mg twice daily; placebo, two puffs qid
Study: 25588394
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg 1 time per day for 3 days
Study: 25588394
Drug: Azithromycin 500
Normalized name: azithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azithromycin 500 mg 1 time per day for 7 days followed by 500 mg 1 time per week for 12 weeks
Study: 25588394
Drug: Long-term adjunctive
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term adjunctive azithromycin
Study: 18217152
Drug: Atorvastatin 80
Normalized name: atorvastatin 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 80 mg/day for six months
Study: 2901125
Drug: Flupentixol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 1 mg
Study: 2901125
Drug: Flupentixol 2
Normalized name: flupenthixol 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 2 mg
Study: 2901125
Drug: Flupentixol 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupentixol 1 mg + Diazepam 15 mg
Study: 31032524
Drug: Magnetic-Controlled Capsule
Normalized name: MAGNESIA
DrugBank: Magnesium oxide (DB01377)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Magnetic-Controlled Capsule Endoscopy (MCE)
Study: 29091217
Drug: Cobicistat-boosted elvitegravir
Normalized name: cobicistat / elvitegravir / emtricitabine / tenofovir disoproxil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobicistat-boosted elvitegravir (150/150 mg)
Study: 26863333
Drug: Prostaglandin vaginal
Normalized name: Prostaglandin D2
DrugBank: Prostaglandin D2 (DB02056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostaglandin vaginal inserts (dinoprostone 10 mg, misoprostol 50 mcg or 100 mcg)
Study: 18419630
Drug: Fluconazole 100
Normalized name: fluconazole 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluconazole 100 mg oral suspension once daily
Study: 18419630
Drug: Placebo oral
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral suspension once daily
Study: 16864931
Drug: ARB plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB plus spironolactone (SPRL) 25 mg/day for 6 months
Study: 16864931
Drug: ARB (candesartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARB (candesartan 8 mg/day) for 1 year
Study: 22854050
Drug: Activated HER-receptors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated HER-receptors (pHER1, pHER2, pHER3)
Study: 20669668
Drug: Ningxintong Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ningxintong Granule (NXTG) combined with Western medical conventional treatment
Study: 20669668
Drug: Western medical
Normalized name: Western wheatgrass
DrugBank: Pascopyrum smithii pollen (DB10719)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medical conventional treatment alone
Study: 10984081
Drug: Diltiazem (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem (90 mg single dose)
Study: 1281046
Drug: EDX-L (epirubicin-lipiodol
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDX-L (epirubicin-lipiodol emulsion)
Study: 1281046
Drug: EDX-L followed
Normalized name: EDX-502
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDX-L followed by GS (gelatin sponge)
Study: 1281046
Drug: DX-L (doxorubicin-lipiodol
Approvals — FDA: no, EMA: no, PMDA: no
Description: DX-L (doxorubicin-lipiodol emulsion)
Study: 3969014
Drug: Calcitonin alternating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin alternating with growth hormone (combined treatment)
Study: 30040016
Drug: 3 weeks
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 weeks of textured balance board training (1 minute daily)
Study: 30040016
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of textured balance board training (1 minute daily)
Study: 29489681
Drug: PO-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO-based administration set
Study: 29489681
Drug: PU-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PU-based administration set
Study: 29489681
Drug: PVC-based administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVC-based administration set
Study: 27103982
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) at a target dose of 60 mg/kg/day in three divided doses
Study: 23342619
Drug: Cytoflavin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cytoflavin (in infusion, then oral administration)
Study: 23342619
Drug: Baseline therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline therapy (alpha1‐adrenoblockers, non‐specific anti‐inflammatory drugs, digital prostate massage and vacuum phallostimulation)
Study: 17703122
Drug: In-home psychotherapy
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In-home psychotherapy for depressive symptoms; details on dosage and duration not specified.
Study: 7715941
Drug: Outpatient cognitive-behavioural
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient cognitive-behavioural therapy (CBT) with amitriptyline (AMI)
Study: 7715941
Drug: Supportive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supportive therapy with amitriptyline (AMI)
Study: 2611615
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of IFN with vinblastine (0.1 mg/kg every third week)
Study: 28347975
Drug: Daily text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily text message reminders for a 30‐day intervention phase following hospitalization.
Study: 24138537
Drug: LPV/r 600/150
Approvals — FDA: no, EMA: no, PMDA: no
Description: LPV/r 600/150 mg
Study: 19496959
Drug: Venlafaxine 150-225
Normalized name: venlafaxine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Venlafaxine 150-225 mg
Study: 11269898
Drug: Control (drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (drugs only)
Study: 3969035
Drug: Smoking intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking intervention programme administered by general practitioners
Study: 25933728
Drug: Liberal RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liberal RBC transfusion strategy (Hb < 11.3 g/dL, 7 mmol/L)
Study: 25933728
Drug: Restrictive RBC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Restrictive RBC transfusion strategy (Hb < 9.7 g/dL, 6 mmol/L)
Study: 23903529
Drug: Bovine colostrum
Normalized name: Bovine Colostrum
DrugBank: Bos taurus colostrum (DB19249)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bovine colostrum protein concentrate (CPC) supplementation (10 g/day)
Study: 23903529
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (10 g whey protein concentrate/day)
Study: 22077684
Drug: Oral and
Normalized name: Tridate, oral and rectal kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral and dental education in one session for children and parents
Study: 19936370
Drug: OptiNose's novel
Approvals — FDA: no, EMA: no, PMDA: no
Description: OptiNose's novel delivery device (Opt‐FP) 400 microg twice daily for 12 weeks
Study: 13680266
Drug: recombinant follicle‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle‐stimulating hormone (rFSH) + human menopausal gonadotrophin (HMG)
Study: 13680266
Drug: recombinant follicle‐stimulating
Approvals — FDA: no, EMA: no, PMDA: no
Description: recombinant follicle‐stimulating hormone (rFSH) alone
Study: 13680266
Drug: short protocol
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: short protocol with luteinizing hormone (LH) added from the beginning
Study: 13680266
Drug: high day
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: high day 3 serum FSH concentrations (>9 mIU/ml)
Study: 11273950
Drug: Ketoprofen (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoprofen (100 mg IV during surgery and 8 hours later)
Study: 9228494
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (ISDN) patch therapy
Study: 8427034
Drug: Influenza subunit
Normalized name: covid-19, protein subunit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Influenza subunit vaccine (0, 10, 20, and 60 micrograms)
Study: 3036023
Drug: Nalidixic acid
Normalized name: Nalidixic Acid
DrugBank: Nalidixic acid (DB00779)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nalidixic acid (2%) applied twice daily under occlusion
Study: 3036023
Drug: Novobiocin (2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novobiocin (2% or 5%) applied twice daily under occlusion
Study: 27240787
Drug: Raltegravir group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raltegravir group (oral ritonavir-boosted lopinavir 100 mg ritonavir, 400 mg lopinavir plus 400 mg raltegravir twice a day)
Study: 18266660
Drug: Vitamin K
Normalized name: Vitamin K
DrugBank: Phylloquinone (DB01022)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin K antagonist (VKA)‐naive paroxysmal AF
Study: 12832367
Drug: Oxytocin antagonist
Normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oxytocin antagonist (atosiban)
Study: 8447842
Drug: Intramuscular administration
Normalized name: Japanese Encephalitis vaccine for intramuscular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular administration of 2 mg folic acid
Study: 8447842
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of 2 mg folic acid
Study: 2447860
Drug: Peripheral intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peripheral intravenous crystalloid solution and routine ward observations
Study: 2447860
Drug: Peritoneal lavage
Normalized name: Peritoneal Lavage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peritoneal lavage as adjunctive therapy
Study: 24002913
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no antiplatelet agents)
Study: 15881644
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy (CT) plus a composition of replaceable amino acids (CRAA) sublingually and orally
Study: 15881644
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy (CT) plus melatonin in doses of 3 and 6 mg
Study: 15881644
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy (CT) only
Study: 15881644
Drug: Complex therapy
Normalized name: hesperidin complex
DrugBank: Citrus bioflavonoids (DB14586)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Complex therapy (CT) plus placebo
Study: 12882479
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity (150 min weekly of moderate intensity physical activity, such as brisk walking)
Study: 9779029
Drug: Enoxaparin (lower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoxaparin (lower dose 1.0 mg/kg)
Study: 8681499
Drug: Tolrestat 200
Normalized name: tolrestat 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tolrestat 200 mg orally once daily for six months
Study: 2796443
Drug: mecillinam (1.200
Approvals — FDA: no, EMA: no, PMDA: no
Description: mecillinam (1.200 mg/day p.o.) for 5 days
Study: 2796443
Drug: co‐trimoxazole (1.600
Approvals — FDA: no, EMA: no, PMDA: no
Description: co‐trimoxazole (1.600 mg/day p.o.) for 5 days
Study: 682818
Drug: Subcutaneous lateral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous lateral sphincterotomy
Study: 27130038
Drug: Facial botulinum
Normalized name: Clostridium botulinum
DrugBank: Clostridium botulinum (DB14223)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Facial botulinum Toxin‐A (BTX) injections
Study: 25002389
Drug: Cold static
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold static storage with histidine-tryptophan-ketoglutarate solution (Custodiol)
Study: 20568303
Drug: peginterferon (PEG‐IFN)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon (PEG‐IFN) alfa‐2b at 1.5 microg/kg/week with ribavirin (RBV) at 800 to 1400 mg/day
Study: 20568303
Drug: peginterferon (PEG‐IFN)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon (PEG‐IFN) alfa‐2b at 1.0 microg/kg/week with RBV at 800 to 1400 mg/day
Study: 20568303
Drug: peginterferon (PEG‐IFN)
Normalized name: peginterferon alfa-2a Injection [Pegasys]
Approvals — FDA: no, EMA: no, PMDA: no
Description: peginterferon (PEG‐IFN) alfa‐2a at 180 microg/week with RBV at 1000 to 1200 mg/day
Study: 3530158
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 1 mg daily
Study: 10081520
Drug: Betaine 4
Normalized name: betaine 460 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaine 4 g daily
Study: 7751897
Drug: Cisplatin (CDDP)
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin (CDDP) 100 mg/m2 intravenously on day 1 and Fluorouracil (FU) 5,000 mg/m2 over a 120-hour continuous infusion
Study: 7751897
Drug: Carboplatin (CBDCA)
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Carboplatin (CBDCA) 400 mg/m2 over a 24-hour continuous infusion on day 1 and Fluorouracil (FU) with the same schedule